Noctrix Health vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
Maker of Nidra, the first FDA-authorized drug-free device for drug-refractory Restless Legs Syndrome. ~$24M ARR; acquired by ResMed for $340M (expected close June 2026).
About
Noctrix Health is a medical device company commercializing Nidra Therapy — the first and only FDA-authorized, drug-free treatment for drug-refractory Restless Legs Syndrome (RLS). The Nidra device uses Tonic Motor Activation (TOMAC) technology to deliver gentle electrical stimulation to the legs, reducing RLS symptoms without pharmaceutical side effects. The FDA granted De Novo authorization in 2023. In August 2025, Noctrix raised $33.5M in combined debt and equity to accelerate U.S. commercialization, reaching an annual revenue run rate of approximately $24M. ResMed signed an agreement in 2026 to acquire Noctrix Health for $340M, with the transaction expected to close around June 1, 2026 — Noctrix''s revenue will be reported within ResMed''s Americas Devices category post-close.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.